Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179783 | 0.89 | OPRM1 (0.54) | OPRM1OPRK1OPRL1CDC25A | |
| SCHEMBL20230142 | 0.87 | OPRM1 (0.71) | OPRM1OPRK1OPRL1KCNH2 | |
| SCHEMBL15848308 | 0.87 | OPRM1 (0.47) | OPRM1OPRK1OPRL1L3MBTL1CYP1A2 | |
| SCHEMBL21179714 | 0.86 | OPRM1 (0.53) | OPRM1OPRK1OPRL1CYP1A2CDC25A | |
| SCHEMBL21179778 | 0.85 | OPRM1 (0.55) | OPRM1OPRK1OPRL1CDC25A | |
| SCHEMBL20213229 | 0.84 | OPRM1 (0.73) | OPRM1OPRK1OPRL1 | |
| SCHEMBL20230138 | 0.84 | OPRM1 (0.73) | OPRM1OPRK1OPRL1 | |
| SCHEMBL20213228 | 0.84 | OPRM1 (0.73) | OPRM1OPRK1OPRL1 | |
| SCHEMBL21179718 | 0.84 | OPRM1 (0.53) | OPRM1OPRK1OPRL1CDC25A | |
| SCHEMBL15848623 | 0.83 | OPRM1 (0.54) | OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRK1 2/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.